JP2025501458A - 疾患の性特異的治療のためのｎａｐ - Google Patents
疾患の性特異的治療のためのｎａｐ Download PDFInfo
- Publication number
- JP2025501458A JP2025501458A JP2024533944A JP2024533944A JP2025501458A JP 2025501458 A JP2025501458 A JP 2025501458A JP 2024533944 A JP2024533944 A JP 2024533944A JP 2024533944 A JP2024533944 A JP 2024533944A JP 2025501458 A JP2025501458 A JP 2025501458A
- Authority
- JP
- Japan
- Prior art keywords
- day
- pharmaceutical composition
- disease
- subject
- nap
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Zoology (AREA)
- Otolaryngology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163289174P | 2021-12-14 | 2021-12-14 | |
| US63/289,174 | 2021-12-14 | ||
| US202263306146P | 2022-02-03 | 2022-02-03 | |
| US63/306,146 | 2022-02-03 | ||
| PCT/IL2022/051314 WO2023112025A1 (en) | 2021-12-14 | 2022-12-13 | Nap for sex-specific treatment of diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025501458A true JP2025501458A (ja) | 2025-01-22 |
| JP2025501458A5 JP2025501458A5 (https=) | 2025-12-18 |
Family
ID=86773996
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024533944A Pending JP2025501458A (ja) | 2021-12-14 | 2022-12-13 | 疾患の性特異的治療のためのｎａｐ |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250312408A1 (https=) |
| EP (1) | EP4447994A4 (https=) |
| JP (1) | JP2025501458A (https=) |
| KR (1) | KR20240135692A (https=) |
| AU (1) | AU2022410066A1 (https=) |
| CA (1) | CA3240138A1 (https=) |
| IL (1) | IL313226A (https=) |
| MX (1) | MX2024006777A (https=) |
| WO (1) | WO2023112025A1 (https=) |
-
2022
- 2022-12-13 WO PCT/IL2022/051314 patent/WO2023112025A1/en not_active Ceased
- 2022-12-13 AU AU2022410066A patent/AU2022410066A1/en active Pending
- 2022-12-13 CA CA3240138A patent/CA3240138A1/en active Pending
- 2022-12-13 IL IL313226A patent/IL313226A/en unknown
- 2022-12-13 EP EP22906851.5A patent/EP4447994A4/en active Pending
- 2022-12-13 MX MX2024006777A patent/MX2024006777A/es unknown
- 2022-12-13 JP JP2024533944A patent/JP2025501458A/ja active Pending
- 2022-12-13 US US18/718,925 patent/US20250312408A1/en active Pending
- 2022-12-13 KR KR1020247022758A patent/KR20240135692A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4447994A1 (en) | 2024-10-23 |
| IL313226A (en) | 2024-07-01 |
| CA3240138A1 (en) | 2023-06-22 |
| WO2023112025A1 (en) | 2023-06-22 |
| AU2022410066A1 (en) | 2024-07-25 |
| MX2024006777A (es) | 2024-08-06 |
| KR20240135692A (ko) | 2024-09-11 |
| US20250312408A1 (en) | 2025-10-09 |
| EP4447994A4 (en) | 2026-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Cao et al. | Advances in developing novel therapeutic strategies for Alzheimer’s disease | |
| Chou et al. | INPP5D regulates inflammasome activation in human microglia | |
| Curcio-Morelli et al. | Macroautophagy is defective in mucolipin-1-deficient mouse neurons | |
| Bachurin et al. | Mild cognitive impairment due to Alzheimer disease: Contemporary approaches to diagnostics and pharmacological intervention | |
| Vilchez et al. | The role of protein clearance mechanisms in organismal ageing and age-related diseases | |
| Ho et al. | Diet‐induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease | |
| Guo et al. | Alzheimer's disease and retinal neurodegeneration | |
| Caldeira et al. | Microglia change from a reactive to an age-like phenotype with the time in culture | |
| Bachmeier et al. | Role of the cannabinoid system in the transit of beta-amyloid across the blood–brain barrier | |
| Wang et al. | Ursolic acid ameliorates amyloid β-induced pathological symptoms in Caenorhabditis elegans by activating the proteasome | |
| Teich et al. | Translational inhibition of APP by Posiphen: Efficacy, pharmacodynamics, and pharmacokinetics in the APP/PS1 mouse | |
| US20100324079A1 (en) | Medicament for prophylaxis and treatment of Alzheimer disease | |
| Zhang et al. | Death-associated protein kinase 1 as a therapeutic target for Alzheimer's disease | |
| EP3897670A1 (en) | Inhibitors of sarm1 in combination with neuroprotective agents | |
| Morsy et al. | Current and emerging pharmacological targets for the treatment of Alzheimer’s disease | |
| Jia et al. | Exendin-4, a glucagon-like peptide 1 receptor agonist, protects against amyloid-β peptide-induced impairment of spatial learning and memory in rats | |
| US20180217163A1 (en) | Treatment of neurodegenerative conditions using pkc activators after determining the presence of the apoe4 allele | |
| Olsson et al. | Imatinib treatment and Aβ42 in humans | |
| Straten et al. | Influence of lithium treatment on GDNF serum and CSF concentrations in patients with early Alzheimer's disease | |
| Xiao | Levetiracetam might act as an efficacious drug to attenuate cognitive deficits of Alzheimer’s disease | |
| Antony et al. | Recent advances in Alzheimer’s disease therapy: clinical trials and literature review of novel enzyme inhibitors targeting amyloid precursor protein | |
| JP2025501458A (ja) | 疾患の性特異的治療のためのｎａｐ | |
| Di Lucente et al. | The impact of mild episodic ketosis on microglia and hippocampal long‐term depression in 5xFAD mice | |
| HK40117549A (zh) | 用於疾病的性别特异性治疗的nap | |
| CN118678965A (zh) | 用于疾病的性别特异性治疗的nap |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240808 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20251210 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20251210 |